Bide Pharmatech News

Bide Pharmaceutical (688073) 2024 three-quarter report review: Overseas markets continue to gain strength, and the business trend is improving steadily

Huachuang SecuritiesNov 12 00:00

Bide Pharmaceutical (688073): Profitability continues to improve, and revenue grows steadily

caitong securitiesOct 25 19:51

Bide Pharmaceuticals (688073): Structural adjustment shows that it has broken out of a profit low

zheshang securitiesOct 25 00:00

Bide Pharmaceutical (688073): Looking forward to continued strength in overseas markets

Sep 2 16:46

Bide Pharmaceutical (688073): Overseas contributions to core performance growth, short-term profits are under pressure

Sep 1 00:00

Bide Pharmaceutical (688073): Overseas advantages continue to be optimistic about improving quality and efficiency

May 14 15:32

Bide Pharmaceutical (688073): The quarterly business trend is improving, and we look forward to continued strength in overseas markets

May 6 18:46

Bide Pharmaceutical (688073): Quarterly operations tend to be steady and optimistic about the company's long-term development

Apr 28 00:00

Open Source Securities released a research report on April 26 stating that it gave Bide Pharmaceutical (688073.SH) a purchase rating. The main reasons for the rating include: 1) accelerating the global layout and continuing high growth in overseas busines

Zhitong FinanceApr 26 22:20

Bide Pharmaceutical (688073) Company Information Update Report: Steady growth in operating revenue awaits profit release in 2024

Apr 26 00:00

Bide Pharmaceutical (688073) Company Information Update Report: Steady Revenue Growth, Phased Pressure on Profit Side

Nov 17, 2023 00:00

Bide Pharmaceutical (688073): Short-term performance pressure is optimistic that overseas markets will continue to gain strength

Nov 9, 2023 10:06

Bide Pharmaceutical (688073): Short-term performance under pressure, “core competitiveness” lays the driving force for the company's long-term growth

Oct 30, 2023 00:00

Bide Pharmaceuticals (688073): Rapid growth in revenue, fluctuations in gross margin disrupt profits

Oct 29, 2023 00:00

Bide Pharmaceutical (688073) Company Brief Review Report: Q2 Performance Reaches New Heights, Continued Optimization of Management Efficiency

首創證券Sep 14, 2023 00:00

Bide Pharmaceutical (688073): Performance maintained strong growth and market share increased steadily

中信證券Sep 7, 2023 15:46

Bide Pharmaceutical (688073) 2023 Interim Report Review: Q2 Meets Expectations, Inventory Turnover Rate Has Increased Significantly

光大證券Sep 5, 2023 13:42

Bide Pharmaceutical (688073): Consolidate how fast it is to consolidate the advantages of the province and maintain rapid growth

財通證券Sep 5, 2023 00:00

Bide Pharmaceutical (688073): Continued high growth in performance highlights the company's α under pressure from industry demand

開源證券Sep 4, 2023 00:00

Bide Pharmaceutical (688073): Continued high performance growth, overseas market growth can be expected

德邦證券Sep 3, 2023 15:16